Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Download FileDr. Robert Carnahan, Ph.D., discusses how the Beacon system helped enable the rapid discovery functional antibodies against SARS-CoV-2.
Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.
Learn about accelerating target-to-lead antibody candidate selection with the Beacon platform in this Antibody Engineering & Therapeutics Digital Week 2019 webinar.